Compare Hyatt Hotels Corporation (H) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs IDEXX Laboratories, Inc. — how do they compare? Hyatt Hotels Corporation trades at $161.94 (market cap $15.02B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.7× Hyatt Hotels Corporation's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| H | IDXX | |
|---|---|---|
Market Cap | $15.02B | $40.43B |
Volume | 842,340 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $766.68 |
52-Week Low | $135.42 | $504.70 |
Typical Hold Time | 148 Days | 46 Days |
Enterprise Value | $18.93B | $41.32B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corporation (H) trades at $159.43, up 1.46% today, with a neutral technical stance and mixed fundamentals. The stock has beaten earnings estimates for three consecutive quarters, but profitability metrics remain thin with a net margin of 1.1% and elevated P/E of 196.83. Recent news highlights brand expansion and a strategic loyalty collaboration with Delta Air Lines, signaling growth initiatives amid a challenging profit environment.
The outlook balances growth potential from fee expansion and new partnerships against high valuation and earnings volatility. Risks include project delays, debt levels, and regional economic sensitivity. Analyst consensus is a Moderate Buy with a $197.77 price target, suggesting 24% upside, but investors face headwinds from margin pressure and competitive dynamics in the hospitality sector.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
